Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma

**Background:** For patients with locally advanced or metastatic urothelial carcinoma (la/mUC), prognosis is poor and effective treatment options are limited. Erdafitinib is an oral fibroblast growth factor receptor (FGFR) kinase inhibitor approved by the FDA for the treatment of adults with la/mUC...

Full description

Saved in:
Bibliographic Details
Main Authors: Suzy Van Sanden, Ayman Youssef, Simona Baculea, Keith Stubbs, Spyros Triantos, Zijiao Yuan, Caitlin Daly
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2024-08-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.120954
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items